Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Sirolimus-Coated vs Paclitaxel-Coated DCBs in ACS Treatment

NCT: NCT07514988 · NOT_YET_RECRUITING

NCT IDNCT07514988
StatusNOT_YET_RECRUITING
Start Date2026-05-01
Completion2028-07-01

Brief Summary

This study aims to investigate and compare the local inflammatory responses and plaque healing characteristics between sirolimus-coated and paclitaxel-coated coronary drug-coated balloons in patients with acute coronary syndrome.

Frequently Asked Questions

What is Sirolimus-Coated vs Paclitaxel-Coated DCBs in ACS Treatment?

Sirolimus-Coated vs Paclitaxel-Coated DCBs in ACS Treatment is a clinical trial registered under NCT07514988. Current status: NOT_YET_RECRUITING.

What is the status of NCT07514988?

The current status of NCT07514988 (Sirolimus-Coated vs Paclitaxel-Coated DCBs in ACS Treatment) is: NOT_YET_RECRUITING.

When did Sirolimus-Coated vs Paclitaxel-Coated DCBs in ACS Treatment start?

Sirolimus-Coated vs Paclitaxel-Coated DCBs in ACS Treatment started on 2026-05-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑